Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.


TSXV:THRM - Post by User

Post by Smokey1958on Jun 29, 2021 5:34pm
590 Views
Post# 33470431

This NR May Be Even Bigger Than We Think

This NR May Be Even Bigger Than We Think

The CEO of DME Authority wrote this article in 2018. He seems to have a very above average interest in DVTs and would seem to have been looking for a device exactly like Venowave for the last couple of years. After reading this it may be a little clearer as to why a company would accept guaranteeing $10 million minimum in annual purchases starting with an order for 5000 Venowave kits.

https://www.linkedin.cn/pulse/9-truths-dvt-prevention-providers-must-consider-best-outcomes-gosse?trk=public_profile_article_view

As an aside, published on the CDC website in the US there are as many as 900,000 DVTs in the US annually. Of those up to 100,000 die. Erick Gosse refers to it as "an epidemic" in his article.



 

<< Previous
Bullboard Posts
Next >>